Earnings Recaps

Browse reported earnings of the most popular stocks

Nov 13, 2026 Nov 12, 2026 Nov 11, 2026 Nov 10, 2026 Nov 9, 2026 Nov 8, 2026 Nov 7, 2026 Nov 6, 2026 Nov 5, 2026 Nov 4, 2026 Nov 3, 2026 Nov 2, 2026 Nov 1, 2026 Oct 31, 2026 Oct 30, 2026 Oct 29, 2026 Oct 28, 2026 Oct 27, 2026 Oct 26, 2026 Oct 25, 2026 Oct 24, 2026 Oct 23, 2026 Oct 22, 2026 Oct 21, 2026 Oct 20, 2026 Oct 19, 2026 Oct 18, 2026 Oct 17, 2026 Oct 16, 2026 Oct 15, 2026 Oct 14, 2026 Oct 13, 2026 Oct 11, 2026 Oct 10, 2026 Oct 9, 2026 Oct 8, 2026 Oct 7, 2026 Oct 3, 2026 Oct 2, 2026 Oct 1, 2026 Sep 30, 2026 Sep 29, 2026 Sep 27, 2026 Sep 26, 2026 Sep 25, 2026 Sep 24, 2026 Sep 23, 2026 Sep 19, 2026 Sep 18, 2026 Sep 17, 2026 Sep 16, 2026 Sep 14, 2026 Sep 13, 2026 Sep 12, 2026 Sep 11, 2026 Sep 10, 2026 Sep 9, 2026 Sep 8, 2026 Sep 5, 2026 Sep 4, 2026 Sep 3, 2026 Sep 2, 2026 Sep 1, 2026 Aug 31, 2026 Aug 30, 2026 Aug 29, 2026 Aug 28, 2026 Aug 27, 2026 Aug 26, 2026 Aug 25, 2026 Aug 23, 2026 Aug 22, 2026 Aug 21, 2026 Aug 20, 2026 Aug 19, 2026 Aug 18, 2026 Aug 17, 2026 Aug 16, 2026 Aug 15, 2026 Aug 14, 2026 Aug 13, 2026 Aug 12, 2026 Aug 11, 2026 Aug 10, 2026 Aug 9, 2026 Aug 8, 2026 Aug 7, 2026 Aug 6, 2026 Aug 5, 2026 Aug 4, 2026 Aug 3, 2026 Aug 2, 2026 Aug 1, 2026 Jul 31, 2026 Jul 30, 2026 Jul 29, 2026 Jul 28, 2026 Jul 27, 2026 Jul 26, 2026 Jul 25, 2026 Jul 24, 2026 Jul 23, 2026 Jul 22, 2026 Jul 21, 2026 Jul 20, 2026 Jul 19, 2026 Jul 18, 2026 Jul 17, 2026 Jul 16, 2026 Jul 12, 2026 Jul 11, 2026 Jul 10, 2026 Jul 9, 2026 Jul 3, 2026 Jul 2, 2026 Jul 1, 2026 Jun 30, 2026 Jun 28, 2026 Jun 27, 2026 Jun 26, 2026 Jun 25, 2026 Jun 24, 2026 Jun 20, 2026 Jun 19, 2026 Jun 18, 2026 Jun 17, 2026 Jun 15, 2026 Jun 14, 2026 Jun 13, 2026 Jun 12, 2026 Jun 11, 2026 Jun 10, 2026 Jun 9, 2026 Jun 6, 2026 Jun 5, 2026 Jun 4, 2026 Jun 3, 2026 Jun 2, 2026 Jun 1, 2026 May 31, 2026 May 30, 2026 May 29, 2026 May 28, 2026 May 27, 2026 May 26, 2026 May 24, 2026 May 23, 2026 May 22, 2026 May 21, 2026 May 20, 2026 May 19, 2026 May 18, 2026 May 17, 2026 May 16, 2026 May 15, 2026 May 14, 2026 May 13, 2026 May 12, 2026 May 11, 2026 May 10, 2026 May 9, 2026 May 8, 2026 May 7, 2026 May 6, 2026 May 5, 2026 May 4, 2026 May 3, 2026 May 2, 2026 May 1, 2026 Apr 30, 2026 Apr 29, 2026 Apr 23, 2026 Apr 22, 2026 Apr 21, 2026 Apr 20, 2026 Apr 18, 2026 Apr 17, 2026 Apr 16, 2026 Apr 15, 2026 Apr 14, 2026 Apr 13, 2026 Apr 10, 2026 Apr 9, 2026 Apr 8, 2026 Apr 7, 2026 Apr 2, 2026 Apr 1, 2026 Mar 31, 2026 Mar 30, 2026 Mar 26, 2026 Mar 25, 2026 Mar 20, 2026 Mar 19, 2026 Mar 18, 2026 Mar 17, 2026 Mar 16, 2026 Mar 13, 2026 Mar 12, 2026 Mar 11, 2026 Mar 9, 2026 Mar 7, 2026 Mar 6, 2026 Mar 5, 2026 Mar 4, 2026 Mar 3, 2026
141 companies Today

Allied Gold Corporation

AAUC.TO Q3 2026
Reported: 2026-11-07

The stock rose 13.6% after Allied Gold reported Kurmuk’s first production and outlined a sharp production ramp, with 2027 output forecast at 615,000–670,000 ounces. The upside case is balanced by high current costs at Sadiola and the execution still required to reach commercial production at Kurmuk and improve performance at Sadiola.

Key takeaways
  • Kurmuk entered production, with 25,000–35,000 ounces expected in November and December, 55,000–65,000 ounces in Q1 2027, and 240,000–270,000 ounces for 2027.
  • Management expects total gold production to rise to 615,000–670,000 ounces next year, from roughly 379,000 ounces last year and expected this year, and to reach about 800,000 ounces annually by 2029.
  • Sadiola produced approximately 42,300 ounces at AISC of $2,876 per ounce. Management expects higher grades and operational changes to lift production and lower unit costs in coming quarters.
  • Bonikro produced 28,600 ounces at AISC of $1,670 per ounce; Agbaou produced 20,300 ounces at AISC of $2,384 per ounce.
  • Revenue was $358 million, adjusted EBITDA approximately $140 million, and adjusted net earnings $49 million ($0.37 per share). Consolidated AISC was $2,378 per ounce; quarter-end cash was $379 million.

Alaris Equity Partners Income Trust

AD-UN.TO Q3 2026
Reported: 2026-11-07

Alaris fell 8.2% after earnings, with the clearest forward-looking concern being management’s expectation of relatively flat 2027 Partner resets after a period of growth. The quarter also included a CAD 58.9 million non-cash fair value loss and a lower fourth-quarter Partner revenue forecast, despite higher cash flow and revenue year over year.

Key takeaways
  • Partner distribution revenue rose 25.9% year over year to CAD 72.2 million; net distributable cash flow increased 46.4% to CAD 54.7 million, or CAD 1.19 per unit.
  • Management expects 2027 resets, based on Partners’ 2026 performance, to be relatively flat overall.
  • Fourth-quarter Partner revenue is forecast at approximately CAD 53 million, versus CAD 72.9 million in Q3; management attributed the sequential decline mainly to the timing and variability of common distributions.
  • Alaris reported a CAD 6.2 million quarterly loss, including CAD 58.9 million of net unrealized fair value losses. Net book value fell CAD 0.96 per unit to CAD 24.87.
  • The estimated Run Rate Payout Ratio is approximately 63%, below the 65%–70% long-term target range; the company also deployed CAD 188 million into new Partners during the quarter.

Adaptive Biotechnologies Corporation

ADPT Q3 2026
Reported: 2026-11-07

Adaptive’s Q3 results were mixed but broadly steady against a near-flat market reaction: the stock rose 0.4% after the company reported total-company profitability and raised full-year MRD revenue guidance. Clinical testing and MRD revenue grew, while reimbursement pressure from more frequent testing remains a constraint on realized pricing.

Key takeaways
  • MRD revenue excluding milestones increased 44% year over year; clinical testing volume grew 46% and clinical revenue rose 41%.
  • Adaptive delivered nearly 40,000 clonoSEQ tests, up 10% sequentially. Blood-based testing grew 68% year over year and made up 51% of total clonoSEQ volume.
  • Total-company gross margin was 76%; free cash flow was $8 million, and quarter-end cash was approximately $386 million. Management said the company reached profitability ahead of expectations.
  • U.S. average selling price was $1,380, up 3% year over year and relatively flat sequentially. More frequent Medicare testing is putting pressure on realized ASP, particularly in multiple myeloma.
  • Management raised full-year 2026 MRD revenue guidance, but the excerpt provides no revised guidance figure. It also said the company remains on track to announce a path forward for the immune medicine separation by year-end.

Community

See what investors are trading, holding, and sharing

🌐
All
📈
Stock
📊
ETF
🏦
Mutual Fund
🪙
Crypto
💱
Forex
# Asset Price Community % Type Currency Sector
Loading...